PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility - Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide unveils new facility
Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility

 

NewswireToday - /newswire/ - Cambridgeshire, United Kingdom, 2010/09/14 - Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide unveils new facility.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Quotient Bioresearch has officially opened its new, state-of-the-art radiochemistry facility in Cardiff, UK, with a ceremony including a VIP opening by the First Minister of Wales, Carwyn Jones.

The new facility, which has been named “The Old Glassworks”, represents a £15 Million investment for Quotient, which was assisted by International Business Wales, the inward investment arm of the Welsh Assembly Government. The Old Glassworks produces radiolabelled compounds, enabling Quotient to support the product development needs of the pharmaceutical, biotechnology and agrochemicals industries worldwide. From the new facility, Quotient is able to manufacture custom radiolabelled drugs for use in both pre-clinical and clinical settings, serving over 250 clients worldwide.

The Old Glassworks houses the largest and most experienced team of radiosynthesis chemists in the world and has already created approximately 25 new jobs, bringing the total number of Quotient employees to over 600. The new facility follows the company’s acquisition of Amersham Radiolabeling Services from GE Healthcare in June 2009 and has enabled seventy-five highly-skilled chemists and support staff to be transferred.

The official ceremony included a VIP opening and unveiling of a plaque by the First Minister of Wales, as well as a speech by Stephen Lewinton, Managing Director for Chemistry and Metabolism at Quotient Bioresearch. Presentations were given by company executives and scientists, discussing the challenges involved in building the new facility, and recommendations for effective experimental design. Guests were also given tours of the facility to view Quotient’s world-class technology.

Paul Cowan, Chairman & Chief Executive Officer, Quotient Bioresearch, said: “We are delighted to announce the official opening of Quotient’s new state-of-the-art facility in Cardiff, Wales. The new facility, which is equipped with world-leading technology, will enable Quotient to offer a bespoke service for the custom synthesis of carbon-14 and tritium labelled compounds.”

Carwyn Jones, First Minister of Wales, said “The Cardiff facility is a centre of excellence for the manufacture of radiolabelled compounds to support Quotient’s pharmaceutical and biotechnology client’s ongoing research and development programmes. The use of radiolabelled compounds is critical to evaluating the safety of new medicines being developed to benefit people with a wide range of illnesses, in both the UK and the rest of the world.”

To learn more about the new facility or Quotient, please call +44 (0)2920 474 900, email info.amersham[.]quotientbioresearch.com

About Quotient Bioresearch
Quotient (quotientbioresearch.com) is a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide. The company offers a unique range of drug development services through its three key focus areas – Chemistry & Metabolism, Bioanalytical Sciences and Clinical Services. Quotient has grown rapidly in the past three years, through a combination of both acquisition-led and organic growth. Quotient Bioresearch is part of Quotient Bioresearch Group, which comprises Quotient Bioresearch and HFL Sport Science.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sarah Evans - Scottpr.com 
+44 1477 539539 quotient[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)